Hjem › Glioblastom › New York › New York City
Kliniske studier for Glioblastom i New York City, NY
30 studier for Glioblastom søker deltakere på steder i og rundt New York City (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM
RekruttererFase 3
- Weill Cornell Medicine, New York
- NewYork-Presbyterian / Columbia University Irving Medical Center, New York
- Lennox Hill Hospital, New York
Ruxolitinib With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma
RekruttererFase 2
- New York University Langone's Perlmutter Cancer Institute, New York
Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment
RekruttererFase 1/2
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
RekruttererFase 2/3
- Icahn School of Medicine at Mount Sinai, New York
- Columbia University Medical Center, New York
- Memorial Sloan Kettering Cancer Center*, New York
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
RekruttererFase 2
- Columbia University Irving Medical Center, New York
A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM
RekruttererFase 1
- Lenox Hill Hospital, New York
A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma
RekruttererFase 1/2
- New York University Langone Medical Center, New York
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
ERAS-801 for the Treatment of Resectable and Progressive or Recurrent or Elderly Newly Diagnosed IDH Wildtype Grade IV Glioblastoma or Gliosarcoma With an EGFR Amplification or Mutation, ERAS801-SARG Trial
RekruttererFase 1
- Memorial Sloan Kettering Cancer Center, New York
Temporally-Modulated Pulsed Radiation Therapy Versus Standard Radiation Therapy for the Treatment of Newly Diagnosed, IDH Wildtype, MGMT-Unmethylated Glioblastoma
RekruttererFase 3
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
RekruttererFase 1/2
- Icahn School of Medicine at Mount Sinai - Oncology, New York
- Memorial Sloan Kettering Cancer Center New York - Main Campus, New York
Study of ABBV-637 or ABBV-155 With ERAS-801 for People With Glioblastoma
RekruttererFase 1
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma
RekruttererFase 1
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
RekruttererFase 3
- NYU Langone Health, New York
- Icahn School of Medicine at Mount Sinai, New York
- Columbia University Medical Center, New York
- og 1 flere
INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)
RekruttererFase 2
- Memorial Sloan Kettering Cancer Center, New York
A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade Glioma
RekruttererFase 1
- NYU Langone Health, New York
Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Glioblastoma
Rekrutterer
- NYU Langone Health, New York
Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed Glioblastoma
RekruttererFase 2
- New York Langone, New York
- Columbia University, New York
- Memorial Sloan Kettering Cancer Center, New York
DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)
RekruttererFase 2
- Lenox Hill Hospital, New York
A Study of 177Lu-PSMA-617 in People With Gliomas
RekruttererFase 1
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
RekruttererFase 1/2
- Lenox Hill Brain Tumor Center, New York
Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM
RekruttererFase 3
- Lenox Hill Brain Tumor Center, New York
Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA
RekruttererFase 1/2
- Lenox Hill Brain Tumor Center, New York
Surgical Tissue Flap to Bypass the Blood Brain Barrier in Glioblastoma
Rekrutterer
- Lenox Hill Brain Tumor Center, New York
Omental Tissue Autograft in Human Recurrent Glioblastoma Multiforme (rGBM)
Rekrutterer
- Lenox Hill Brain Tumor Center, New York
Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM
RekruttererFase 1/2
- Lenox Hill Brain Tumor Center, New York
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RekruttererFase 1/2
- NYU Langone Health, New York
- Memorial Sloan Kettering Cancer Center, New York
Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
RekruttererFase 2
- Lenox Hill Brain Tumor Center, New York
Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer
RekruttererFase 2
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RekruttererObservasjonsstudie
- Massive Bio SYNERGY-AI site, New York
Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma
RekruttererFase 1
- Columbia University Medical Center - Herbert Irving Pavilion, New York
Glioblastom-studier i andre byer
- Boston, MA28 studier
- Houston, TX26 studier
- Los Angeles, CA24 studier
- Durham, NC20 studier
- San Francisco, CA17 studier
- Chicago, IL15 studier
- Washington, DC15 studier
- Columbus, OH14 studier
- Miami, FL14 studier
- Rochester, MN13 studier
- Jacksonville, FL13 studier
- Aurora, CO12 studier
Andre studier i New York City
- Brystkreft136 studier
- Ikke-småcellet lungekreft121 studier
- Kreft (alle typer)109 studier
- Prostatakreft103 studier
- Metastatisk kreft93 studier
- Kolorektal kreft78 studier
- Eggstokkreft69 studier
- Lungekreft60 studier
- Multipelt myelom60 studier
- Pankreaskreft60 studier
- Endometriekreft52 studier
- Akut myelogen leukemi51 studier
Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.